Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5

Lysosomotropic agents such as sunitinib, lapatinib, and chloroquine belong to a drug family that is being used more frequently to treat advanced cancers. Sunitinib is standard care for metastatic renal cell carcinomas (mRCC) and lapatinib is used for trastuzumab/pertuzumab-refractory cancers. Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: Giuliano, Sandy, Dufies, Maeva, Ndiaye, Papa Diogop, Viotti, Julien, Borchiellini, Delphine, Parola, Julien, Vial, Valérie, Cormerais, Yann, Ohanna, Mickaël, Imbert, Véronique, Chamorey, Emmanuel, Rioux-Leclercq, Nathalie, Savina, Ariel, Ferrero, Jean-Marc, Mograbi, Baharia, Pagès, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6401402/
https://www.ncbi.nlm.nih.gov/pubmed/30867824
http://dx.doi.org/10.7150/thno.29093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6401402/
https://www.ncbi.nlm.nih.gov/pubmed/30867824
http://dx.doi.org/10.7150/thno.29093

Ejemplares similares